ABUS
Price
$3.17
Change
-$0.11 (-3.35%)
Updated
Jul 11 closing price
Capitalization
607.14M
19 days until earnings call
INO
Price
$1.36
Change
-$0.03 (-2.16%)
Updated
Jul 11, 04:59 PM (EDT)
Capitalization
69.31M
Interact to see
Advertisement

ABUS vs INO

Header iconABUS vs INO Comparison
Open Charts ABUS vs INOBanner chart's image
Arbutus Biopharma
Price$3.17
Change-$0.11 (-3.35%)
Volume$1.12M
Capitalization607.14M
Inovio Pharmaceuticals
Price$1.36
Change-$0.03 (-2.16%)
Volume$11.08K
Capitalization69.31M
ABUS vs INO Comparison Chart in %
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. INO commentary
Jul 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and INO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 12, 2025
Stock price -- (ABUS: $3.17 vs. INO: $1.39)
Brand notoriety: ABUS: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 138% vs. INO: 201%
Market capitalization -- ABUS: $607.14M vs. INO: $69.31M
ABUS [@Biotechnology] is valued at $607.14M. INO’s [@Biotechnology] market capitalization is $69.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 5 bearish.
  • INO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than INO.

Price Growth

ABUS (@Biotechnology) experienced а -2.16% price change this week, while INO (@Biotechnology) price change was +4.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 05, 2025.

INO is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($607M) has a higher market cap than INO($69.3M). ABUS YTD gains are higher at: -3.058 vs. INO (-21.910). ABUS has higher annual earnings (EBITDA): -75.1M vs. INO (-93.37M). ABUS has more cash in the bank: 113M vs. INO (68.4M). ABUS has less debt than INO: ABUS (1.19M) vs INO (11.3M). ABUS has higher revenues than INO: ABUS (6.4M) vs INO (283K).
ABUSINOABUS / INO
Capitalization607M69.3M876%
EBITDA-75.1M-93.37M80%
Gain YTD-3.058-21.91014%
P/E RatioN/AN/A-
Revenue6.4M283K2,263%
Total Cash113M68.4M165%
Total Debt1.19M11.3M11%
FUNDAMENTALS RATINGS
ABUS vs INO: Fundamental Ratings
ABUS
INO
OUTLOOK RATING
1..100
513
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
74100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6193
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (50) in the Medical Specialties industry is in the same range as ABUS (65) in the Biotechnology industry. This means that INO’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's SMR Rating (98) in the Biotechnology industry is in the same range as INO (98) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's Price Growth Rating (61) in the Biotechnology industry is in the same range as INO (93) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSINO
RSI
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GMPXF6.81N/A
N/A
RF Capital Group Inc.
CHRUF5.35N/A
N/A
CHORUS LTD.
SPXSF83.12N/A
N/A
SPIRAX GROUP PLC
FREJN19.60N/A
N/A
Freddie Mac
AUCUF0.19-0.01
-3.00%
Inflection Resources Ltd.

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-3.35%
IDYA - ABUS
47%
Loosely correlated
-1.40%
IMVT - ABUS
44%
Loosely correlated
+3.60%
ARRY - ABUS
43%
Loosely correlated
-2.23%
DNLI - ABUS
43%
Loosely correlated
-5.41%
AXON - ABUS
42%
Loosely correlated
-0.46%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+3.73%
AXON - INO
53%
Loosely correlated
-9.04%
ARRY - INO
52%
Loosely correlated
-0.78%
RPTX - INO
50%
Loosely correlated
-1.27%
ONCO - INO
50%
Loosely correlated
-11.09%
BCYC - INO
48%
Loosely correlated
+7.87%
More